Therefore, it was proposed that the balance between non-SUMOylated and SUMOylated CYLD can direct neuroblastoma cancer cells against differentiation or cell death via regulation of NF-κB signaling [3]. The gene discussed is NFKB1; the disease is neuroblastoma.